Viloxazine hydrochloride - Supernus Pharmaceuticals

Drug Profile

Viloxazine hydrochloride - Supernus Pharmaceuticals

Alternative Names: ICI-58834; SPN 809; SPN-812; SPN-812 ER; SPN-812V; Viloxazine hydrochloride extended release; Viloxazine-hydrochloride

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antidepressants; Behavioural disorder therapies; Morpholines
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase I Depressive disorders

Most Recent Events

  • 06 Nov 2018 Supernus Pharmaceuticals intends to launch viloxazine hydrochloride for Attention-deficit hyperactivity disorder, pending US FDA approval, in the second half of 2020
  • 06 Nov 2018 Supernus Pharmaceuticals intends to submit an NDA for Attention-deficit hyperactivity disorder in the second half of 2019
  • 06 Nov 2018 Supernus Pharmaceuticals completes enrolment in first three phase III trials in Attention-deficit hyperactivity disorder
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top